AU2002230398A1 - Bile-acid conjugates for providing sustained systemic concentrations of drugs - Google Patents
Bile-acid conjugates for providing sustained systemic concentrations of drugsInfo
- Publication number
- AU2002230398A1 AU2002230398A1 AU2002230398A AU3039802A AU2002230398A1 AU 2002230398 A1 AU2002230398 A1 AU 2002230398A1 AU 2002230398 A AU2002230398 A AU 2002230398A AU 3039802 A AU3039802 A AU 3039802A AU 2002230398 A1 AU2002230398 A1 AU 2002230398A1
- Authority
- AU
- Australia
- Prior art keywords
- bile
- drugs
- acid conjugates
- providing sustained
- systemic concentrations
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
- C07C237/12—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23875800P | 2000-10-06 | 2000-10-06 | |
US60/238,758 | 2000-10-06 | ||
US24980400P | 2000-11-17 | 2000-11-17 | |
US60/249,804 | 2000-11-17 | ||
US29747201P | 2001-06-11 | 2001-06-11 | |
US60/297,472 | 2001-06-11 | ||
PCT/US2001/042613 WO2002032376A2 (en) | 2000-10-06 | 2001-10-05 | Bile-acid conjugates for providing sustained systemic concentrations of drugs |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2002230398A1 true AU2002230398A1 (en) | 2002-04-29 |
Family
ID=27399153
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2002230398A Abandoned AU2002230398A1 (en) | 2000-10-06 | 2001-10-05 | Bile-acid conjugates for providing sustained systemic concentrations of drugs |
AU2002213468A Abandoned AU2002213468A1 (en) | 2000-10-06 | 2001-10-09 | Bile-acid conjugates for providing sustained systemic concentrations of drugs |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2002213468A Abandoned AU2002213468A1 (en) | 2000-10-06 | 2001-10-09 | Bile-acid conjugates for providing sustained systemic concentrations of drugs |
Country Status (4)
Country | Link |
---|---|
US (5) | US6900192B2 (en) |
EP (2) | EP1361847A2 (en) |
AU (2) | AU2002230398A1 (en) |
WO (1) | WO2002032376A2 (en) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6900192B2 (en) * | 2000-10-06 | 2005-05-31 | Xenoport, Inc. | Bile-acid conjugates for providing sustained systemic concentrations of drugs |
US20020098999A1 (en) * | 2000-10-06 | 2002-07-25 | Gallop Mark A. | Compounds for sustained release of orally delivered drugs |
EP1343805A4 (en) * | 2000-10-06 | 2005-07-20 | Xenoport Inc | Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration |
US7144877B2 (en) | 2000-10-06 | 2006-12-05 | Xenoport, Inc. | Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs |
US8048917B2 (en) | 2005-04-06 | 2011-11-01 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
WO2002100344A2 (en) | 2001-06-11 | 2002-12-19 | Xenoport, Inc. | Amino acid conjugates providing for sustained systemic concentrations of gaba analogues |
IL159300A0 (en) * | 2001-06-11 | 2004-06-01 | Xenoport Inc | Prodrugs of gaba analogs, compositions and uses thereof |
US7186855B2 (en) | 2001-06-11 | 2007-03-06 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
US6818787B2 (en) | 2001-06-11 | 2004-11-16 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
AU2003243180A1 (en) | 2002-05-17 | 2003-12-12 | Xenoport, Inc. | Amino acid conjugates providing for sustained systemic concentrations of gaba analogues |
US20080026077A1 (en) * | 2002-11-12 | 2008-01-31 | John Hilfinger | Methods and compositions of gene delivery agents for systemic and local therapy |
US20050026859A1 (en) * | 2002-11-12 | 2005-02-03 | John Hilfinger | Methods and compositions of gene delivery agents for systemic and local therapy |
ES2549259T3 (en) | 2003-04-11 | 2015-10-26 | Cargill, Incorporated | Granular systems for preparing drinks |
JP2007505149A (en) | 2003-09-11 | 2007-03-08 | ゼノポート,インコーポレイティド | Treatment and / or prevention of urinary incontinence with prodrugs of GABA analogs |
SG146643A1 (en) | 2003-09-17 | 2008-10-30 | Xenoport Inc | Treating or preventing restless legs syndrome using prodrugs of gaba analogs |
CN1867322B (en) | 2003-10-14 | 2014-06-25 | 什诺波特有限公司 | Crystalline form of gamma-aminobutyric acid analog |
US20050226927A1 (en) * | 2004-04-02 | 2005-10-13 | Impax Laboratories, Inc. | Pharmaceutical dosage forms having immediate release and/or controlled release properties that contain a GABAB receptor agonist |
AU2004274241A1 (en) | 2004-07-06 | 2005-03-31 | Ksr Technologies Co. | Support bracket with an integrated switch for a pedal assembly |
CN102429882B (en) | 2004-11-04 | 2015-03-25 | 什诺波特有限公司 | Gabapentin prodrug sustained release oral dosage forms |
US20070049626A1 (en) * | 2005-08-26 | 2007-03-01 | Tran Pierre V | Treating premature ejaculation using gabapentin and pregabalin prodrugs |
WO2007065036A2 (en) * | 2005-12-02 | 2007-06-07 | Neuromolecular Pharmaceuticals, Inc. | Therapeutic conjugates and methods of using same |
US20090131384A1 (en) * | 2006-03-22 | 2009-05-21 | Syndexa Pharmaceuticals Corporation | Compounds and methods for treatment of disorders associated with er stress |
US20080161400A1 (en) * | 2006-10-26 | 2008-07-03 | Xenoport, Inc. | Use of forms of propofol for treating diseases associated with oxidative stress |
EP2101752A1 (en) * | 2006-12-08 | 2009-09-23 | Xenoport, Inc. | Use of prodrugs of gaba analogs for treating diseases |
US20080261913A1 (en) * | 2006-12-28 | 2008-10-23 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of liver disorders |
US8828665B2 (en) | 2007-02-16 | 2014-09-09 | Ark Diagnostics, Inc. | Compounds and methods for use in detecting gabapentin |
WO2008151306A1 (en) * | 2007-06-05 | 2008-12-11 | Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University | Synthesis of cyclodepsipeptide compounds having antineoplastic and/or antimicrobial activity |
US20090041806A1 (en) * | 2007-06-15 | 2009-02-12 | Xenoport, Inc. | Use of prodrugs of gaba analogs, antispasticity agents, and prodrugs of gaba b receptor agonists for treating spasticity |
US8242294B2 (en) | 2007-06-19 | 2012-08-14 | Kythera Biopharmaceuticals, Inc. | Synthetic bile acid compositions and methods |
US20080318870A1 (en) | 2007-06-19 | 2008-12-25 | Kythera Biopharmaceuticals, Inc. | Synthetic bile acid compositions and methods |
JOP20180077A1 (en) | 2007-06-19 | 2019-01-30 | Kythera Biopharmaceuticals Inc | Synthetic bile acid compositions and methods |
SG176464A1 (en) | 2008-05-09 | 2011-12-29 | Agency Science Tech & Res | Diagnosis and treatment of kawasaki disease |
CA2729168A1 (en) * | 2008-07-02 | 2010-02-04 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
EP2349335B1 (en) | 2008-10-24 | 2013-08-07 | ARK Diagnostics, Inc. | Levetiracetam immunoassays |
AR094621A1 (en) | 2010-04-01 | 2015-08-19 | Idenix Pharmaceuticals Inc | PHARMACEUTICAL COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS |
WO2011133948A2 (en) * | 2010-04-22 | 2011-10-27 | Longevity Biotech, Inc. | Highly active polypeptides and methods of making and using the same |
MX2013001704A (en) | 2010-08-12 | 2013-06-28 | Kythera Biopharmaceuticals Inc | Synthetic bile acid compositions and methods. |
WO2012047495A2 (en) * | 2010-09-27 | 2012-04-12 | Kythera Biopharmaceuticals, Inc. | Methods for preparing synthetic bile acids and compositions comprising the same |
CN107050456B (en) | 2010-09-28 | 2022-08-12 | 加利福尼亚大学董事会 | GABA agonists for the treatment of diseases associated with metabolic syndrome and GABA combinations for the treatment or prevention of type I diabetes |
US9243025B2 (en) | 2011-03-31 | 2016-01-26 | Idenix Pharmaceuticals, Llc | Compounds and pharmaceutical compositions for the treatment of viral infections |
US8741882B2 (en) * | 2012-01-20 | 2014-06-03 | Sen Capital, Llc. | Anti-diabetic compounds |
US9970929B2 (en) | 2013-01-18 | 2018-05-15 | Ark Diagnostics, Inc. | Voriconazole immunoassays |
US9920136B2 (en) | 2013-02-13 | 2018-03-20 | Ark Diagnostics, Inc. | Posaconazole immunoassays |
WO2014145718A2 (en) | 2013-03-15 | 2014-09-18 | Longevity Biotech, Inc. | Peptides comprising non-natural amino acids and methods of making and using the same |
US10040817B2 (en) | 2013-10-03 | 2018-08-07 | Enterin Laboratories, Inc. | Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same |
EP3265074B1 (en) * | 2015-03-03 | 2020-08-12 | ARK Diagnostics, Inc. | Pregabalin immunoassays |
EP4316471A1 (en) | 2021-04-01 | 2024-02-07 | SNJ Pharma Inc | Oral nanoparticles for bioactive compound, and method of preparing same |
Family Cites Families (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1294961B (en) | 1963-03-21 | 1969-08-21 | Merck Ag E | Process for the preparation of 22-azacholestane derivatives and their acid addition salts |
DE2460891C2 (en) * | 1974-12-21 | 1982-09-23 | Gödecke AG, 1000 Berlin | 1-aminomethyl-1-cycloalkaneacetic acids and their esters, processes for their preparation and medicaments containing these compounds |
US4560512A (en) | 1982-09-30 | 1985-12-24 | Merck & Co., Inc. | Derivatives of steroid compounds linked to cyotoxic agents |
DE3435386A1 (en) * | 1984-09-27 | 1986-04-03 | Dr.Ing.H.C. F. Porsche Ag, 7000 Stuttgart | AIR-COOLED MULTI-CYLINDER INTERNAL COMBUSTION ENGINE |
US4866044A (en) | 1985-07-09 | 1989-09-12 | Takeda Chemical Industries, Ltd. | Solubilized composition of poorly-soluble pharmaceutical product |
CH674369A5 (en) | 1986-11-26 | 1990-05-31 | Jago Res Ag | |
DE3930696A1 (en) * | 1989-09-14 | 1991-03-28 | Hoechst Ag | GALLENSAEUREDERIVATE, METHOD FOR THE PRODUCTION THEREOF, USE AS MEDICAMENT |
AU9137091A (en) | 1990-11-27 | 1992-06-25 | Northwestern University | Gaba and l-glutamic acid analogs for antiseizure treatment |
US6197819B1 (en) * | 1990-11-27 | 2001-03-06 | Northwestern University | Gamma amino butyric acid analogs and optical isomers |
CA2134674C (en) | 1992-05-20 | 2004-12-21 | Richard B. Silverman | Gaba and l-glutamic acid analogs for antiseizure treatment |
GB9212511D0 (en) | 1992-06-12 | 1992-07-22 | Cortecs Ltd | Pharmaceutical compositions |
US5352682A (en) | 1993-03-08 | 1994-10-04 | Digestive Care Inc. | Compositions containing salts of bile acid-aminosalicylate conjugates |
NO940115D0 (en) | 1994-01-13 | 1994-01-13 | Nycomed Imaging As | Contrast agents for X-ray and magnetic tomographic imaging |
US5541348A (en) * | 1994-03-10 | 1996-07-30 | National Research Council Of Canada | Bile acids for biological and chemical applications and processes for the production thereof |
DE19508409C1 (en) * | 1995-03-09 | 1996-05-09 | Harting Elektronik Gmbh | Multi-contact plug connector e.g. for circuit board |
US6143738A (en) | 1995-06-07 | 2000-11-07 | Magainin Pharmaceuticals, Inc. | Therapeutic uses for an aminosterol compound |
US5695738A (en) | 1995-06-15 | 1997-12-09 | Glycomed Incorporated | Steroidal C-glycosides |
DE69616554T2 (en) | 1995-06-23 | 2002-07-11 | Mitsubishi Chem Corp | SIALIC DERIVATIVES |
EP0888325B1 (en) | 1996-02-07 | 2002-05-29 | Warner-Lambert Company | Novel cyclic amino acids as pharmaceutical agents |
ES2169848T3 (en) * | 1996-03-14 | 2002-07-16 | Warner Lambert Co | NEW CROWNED CYCLINE AMINO ACIDS AS PHARMACEUTICAL AGENTS. |
US6103932A (en) * | 1996-03-14 | 2000-08-15 | Warner-Lambert Company | Substituted cyclic amino acids as pharmaceutical agents |
CA2263663C (en) | 1996-10-23 | 2006-05-30 | Justin Stephen Bryans | Substituted gamma aminobutyric acids as pharmaceutical agents |
DE29621794U1 (en) * | 1996-12-17 | 1998-04-09 | Bosch Gmbh Robert | Adjustment device, in particular for a sliding / lifting roof of a motor vehicle |
AU8668598A (en) | 1997-08-20 | 1999-03-08 | University Of Oklahoma, The | Gaba analogs to prevent and treat gastrointestinal damage |
JPH1160954A (en) | 1997-08-21 | 1999-03-05 | Toshiba Silicone Co Ltd | Silicone binder composition |
JPH1160594A (en) * | 1997-08-25 | 1999-03-02 | Sankyo Co Ltd | Bile acid derivative |
PL199794B1 (en) | 1997-10-27 | 2008-10-31 | Warner Lambert Co | Intermediate compounds for producing cyclic amino acids derivatives |
ES2216338T3 (en) | 1997-12-16 | 2004-10-16 | Warner-Lambert Company Llc | NOVEDOUS AMINAS AS PHARMACEUTICAL AGENTS. |
EP1045834A1 (en) | 1997-12-16 | 2000-10-25 | Warner-Lambert Company | 4(3)substituted-4(3)-aminomethyl-(thio)pyran or -piperidine derivatives (=gabapentin analogues), their preparation and their use in the treatment of neurological disorders |
JP2002508362A (en) | 1997-12-16 | 2002-03-19 | ワーナー−ランバート・カンパニー | 1-Substituted-1-aminomethyl-cycloalkane derivatives (= gabapentin analogs), their preparation and their use in the treatment of neurological diseases |
NZ506793A (en) | 1998-05-26 | 2003-03-28 | Warner Lambert Co | Conformationally constrained amino acid compounds and their use for treating epilepsy, faintness attacks, hypokinesia, cranial disorders, neurodegenerative disorders, depression, anxiety, panic, pain and neuropathological disorders |
KR20010075064A (en) | 1998-09-14 | 2001-08-09 | 로즈 암스트롱, 크리스틴 에이. 트러트웨인 | Branched alkyl pyrrolidine-3-carboxylic acids |
WO2000023067A1 (en) | 1998-10-16 | 2000-04-27 | Warner-Lambert Company | Method for the treatment of mania and bipolar disorder |
AU1602100A (en) | 1998-11-25 | 2000-06-13 | Warner-Lambert Company | Improved gamma amino butyric acid analogs |
IT1304501B1 (en) * | 1998-12-23 | 2001-03-19 | Bracco Spa | USE OF BILIARY ACID DERIVATIVES CONJUGATED WITH METALLIC COMPLEXES LIKE "BLOOD POOL AGENTS" FOR THE DIAGNOSTIC INVESTIGATION THROUGH RESONANCE |
EP1031350A1 (en) | 1999-02-23 | 2000-08-30 | Warner-Lambert Company | Use of a gabapentin-analog for the manufacture of a medicament for preventing and treating visceral pain |
ATE363074T1 (en) | 1999-09-14 | 2007-06-15 | Xenoport Inc | SUBSTRATES AND SCREENING METHODS FOR TRANSPORT PROTEINS |
CA2405151A1 (en) | 2000-04-07 | 2001-10-18 | University Of Maryland, Baltimore | Bile acid containing prodrugs with enhanced bioavailability |
EP1343805A4 (en) | 2000-10-06 | 2005-07-20 | Xenoport Inc | Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration |
US7144877B2 (en) | 2000-10-06 | 2006-12-05 | Xenoport, Inc. | Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs |
US6900192B2 (en) | 2000-10-06 | 2005-05-31 | Xenoport, Inc. | Bile-acid conjugates for providing sustained systemic concentrations of drugs |
IL159300A0 (en) | 2001-06-11 | 2004-06-01 | Xenoport Inc | Prodrugs of gaba analogs, compositions and uses thereof |
US7053076B2 (en) | 2001-08-29 | 2006-05-30 | Xenoport, Inc. | Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs |
-
2001
- 2001-10-05 US US09/972,283 patent/US6900192B2/en not_active Expired - Fee Related
- 2001-10-05 AU AU2002230398A patent/AU2002230398A1/en not_active Abandoned
- 2001-10-05 EP EP01987653A patent/EP1361847A2/en not_active Withdrawn
- 2001-10-05 WO PCT/US2001/042613 patent/WO2002032376A2/en active Search and Examination
- 2001-10-09 EP EP01981851A patent/EP1347989A1/en not_active Withdrawn
- 2001-10-09 AU AU2002213468A patent/AU2002213468A1/en not_active Abandoned
- 2001-10-09 US US09/974,768 patent/US6984634B2/en not_active Expired - Fee Related
-
2005
- 2005-02-09 US US11/053,324 patent/US7049305B2/en not_active Expired - Fee Related
- 2005-09-06 US US11/218,468 patent/US7598235B2/en not_active Expired - Fee Related
-
2006
- 2006-03-24 US US11/388,021 patent/US7601706B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP1347989A1 (en) | 2003-10-01 |
US7601706B2 (en) | 2009-10-13 |
US20020111338A1 (en) | 2002-08-15 |
US20020142998A1 (en) | 2002-10-03 |
US20050148564A1 (en) | 2005-07-07 |
US7598235B2 (en) | 2009-10-06 |
WO2002032376A2 (en) | 2002-04-25 |
US20060166858A1 (en) | 2006-07-27 |
EP1361847A2 (en) | 2003-11-19 |
US7049305B2 (en) | 2006-05-23 |
US20050288228A1 (en) | 2005-12-29 |
US6900192B2 (en) | 2005-05-31 |
WO2002032376A3 (en) | 2003-09-04 |
US6984634B2 (en) | 2006-01-10 |
AU2002213468A1 (en) | 2002-04-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2002213468A1 (en) | Bile-acid conjugates for providing sustained systemic concentrations of drugs | |
AU2002211863A1 (en) | Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration | |
AU2002243204A1 (en) | Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs | |
AU2001235691A1 (en) | Use of paullone derivatives for making medicines | |
AU2001235726A1 (en) | Device for relative displacement of two bodies | |
AU2001257577A1 (en) | Water-soluble polymer conjugates of artelinic acid | |
AU2001267766A1 (en) | Pyrazole derivatives | |
AU2001242610A1 (en) | Device for measuring a volume of drug | |
AU2882801A (en) | Azepine derivatives | |
AU2002330273A1 (en) | Liposome-encapsulated insulin formulations | |
AU2002258563A1 (en) | Pharmaceutical formulations for sustained release | |
AU2001264887A1 (en) | Drug delivery device | |
AU2001230584A1 (en) | 1h-imidazopyridine derivatives | |
AU2001240026A1 (en) | Camptothecin conjugates | |
AU2002225878A1 (en) | Receptor antagonist-lipid conjugates and delivery vehicles containing same | |
AU2001278694A1 (en) | Avermectin derivatives | |
AU2002214006A1 (en) | Drugs for diabetes | |
AU2002239257A1 (en) | Amino acid conjugates providing for sustained systemic concentrations of gaba analogues | |
AU2001289635A1 (en) | Polymeric conjugates of antitumor agents | |
AU2003287666A1 (en) | Systemic delivery of antiviral agents | |
AU2001248772A1 (en) | Sustained release drug compositions | |
AU2002332713A1 (en) | Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs | |
AU2001259212A1 (en) | Medicated wrap | |
AU2002221099A1 (en) | Combination drugs | |
AU2001230565A1 (en) | Perfluoroisopropylbenzene derivatives |